MyOme Launches CASRcade, a No Charge Family Cascade Genetic Testing Program for Families Affected by ADH1

The program will provide no-charge genetic testing and genetic counseling support for biological relatives, up to fourth degree, of individuals living in the U.S. with confirmed Autosomal Dominant Hypocalcemia Type 1.

MENLO PARK, Calif., Oct. 8, 2026/PRNewswire/ -- MyOme today announced CASRcade, a cascade genetic testing program sponsored by BridgeBio for families affected by Autosomal Dominant Hypocalcemia Type 1 (ADH1), a rare condition, yet a common genetic form of hypoparathyroidism.

Through the program, MyOme will provide no-charge familial variant testing (FVT) and facilitate genetic counseling for eligible biological relatives, up to fourth degree, of individuals with confirmed ADH1. The program is designed to help identify relatives who may have inherited the same variant in the calcium-sensing receptor gene (CASR) associated with ADH1, so they can seek diagnosis and care earlier.

"Genetic conditions often affect entire families, yet identifying at-risk relatives can be challenging," said Akash Kumar, MD, PhD, MyOme Chief Medical Officer. "By expanding access to family cascade genetic testing, we can help more individuals understand whether they carry the same CASR genetic variant and, when appropriate, take informed steps toward proactive care. We're proud to partner with BridgeBio to make this process more accessible and help families affected by ADH1 gain greater clarity about their genetic health."

ADH1 is a genetic form of hypoparathyroidism caused by gain-of-function variants in the CASR gene, which encodes the calcium-sensing receptor (CaSR), a key regulator of parathyroid hormone secretion and renal calcium handling. . Because ADH1 is inherited in an autosomal dominant pattern, each child of an affected parent has a 50% chance of inheriting the variant. Family cascade genetic testing offers a direct way to find those relatives and support proactive health management.

Through CASRcade, participating healthcare providers can enroll patients with confirmed ADH1 through MyOme. Consenting patients can then identify biological relatives who may be eligible to participate in family cascade genetic testing. MyOme will perform targeted genetic sequencing and analysis to determine whether enrolled relatives carry the same CASR variant identified in the family.

Family members who receive a positive result may be able to initiate testing for their own eligible biological relatives, extending the cascade through additional family members. MyOme will also facilitate access to genetic counseling through a qualified third-party provider for family members with confirmed positive results.

About MyOme

MyOme is a clinical whole genome analysis company helping families understand their risk for diseases. As a leader in polygenic and AI-based integrative risk modeling, MyOme's platform combines genome sequencing with AI-driven analytics to integrate polygenic risk scores with established clinical predictors, enabling a more comprehensive approach to disease risk assessment. MyOme leverages the power of the whole-genome and clinical data for a lifetime of clinically meaningful and actionable insights. These capabilities can dramatically reduce healthcare costs and improve outcomes by identifying disease risk earlier and enabling preventive interventions. Certified under the Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP), MyOme is based in Menlo Park, California.

SOURCE MyOme, Inc